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(57) ABSTRACT 
Coated microneedle devices and methods of making such 
devices are provided. In one aspect, a method for coating 
includes providing a microstructure having at least one sur-
face in need of coating; and applying a coating liquid, which 
includes at least one drug, to the at least one surface of the 
microstructure, wherein the surface energy of the coating 
liquid is less than the surface energy of the surface of the 
microstructure. The coating liquid may include a viscosity 
enhancer and surfactant. Microneedles having heterogeneous 
coatings, pockets, or both are also provided. 
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METHOD OF MAKING COATED 
MICROSTRUCTURES 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a divisional of co-pending U.S. appli-
cation Ser. No. 11/917,705, filed Dec. 14, 2007, which is a 
national phase of PCT/US2006/023814, filed Jun. 19, 2006. 
Priority to and benefit of U.S. Provisional Application No. 
60/691,857, filed Jun. 17, 2005, and U.S. Provisional Appli-
cation No. 60/732,267, filed Nov. 11, 2005, is claimed. The 
prior applications are incorporated herein by reference in 
their entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with U.S. govermnent support 
under Contract No. 8 ROI EB00260-03 awarded by the 
National Institute of Health. The U.S. government has certain 
rights in the invention. 
BACKGROUND OF THE INVENTION 
This invention is generally in the field of microneedles 
useful in medical applications, and more particularly to 
coated microneedles for drug delivery and sensing, such as 
transdermally. 
Biopharmaceuticals, such as peptides, proteins, and future 
uses of DNA and RNA, represent a rapidly growing segment 
of pharmaceutical therapies (Walsh, Trends Biotechnol 
23:553-58 (2005)). These drugs are delivered almost exclu-
sively by the parenteral route, as the oral route is generally 
unavailable due to poor absorption, drug degradation, and low 
bioavailability. However, conventional parenteral administra-
tion with hypodermic needles undesirably requires expertise 
for delivery, can lead to accidental needle sticks, and causes 
pain, which results in reduced patient compliance. Given 
these problems, efforts have been made to develop alternate 
drug delivery routes to replace hypodermic needles (Orive et 
al., Curr Opin Biotechnol 14:659-64 (2003)). It would be 
desirable to provide drug delivery methods and devices that 
avoid the limitations and disadvantages associated with the 
use of conventional hypodermic needles. 
Transdermal drug delivery is an especially attractive alter-
native to conventional hypodermic needles, because it is usu-
ally easy to use, safe, and painless (Prausnitz et al., Nat Rev 
Drug Discov 3:115-24 (2004)). The tough barrier posed by 
the skin's outer layer of stratum comeum has limited the 
applicability of this method to drugs that are hydrophobic, 
low molecular weight, and potent, as the stratum comeum's 
barrier properties severely limit passive delivery of most 
drugs, especially macromolecules and microparticles. 
The use of micron-scale needles assembled on a transder-
mal patch has been proposed as a hybrid between hypodermic 
needles and transdermal patches that can overcome the prob-
lems of both injections and patches (Prausnitz et al., Micron-
eedles In Percutaneous Penetration Enhancers (Smithand & 
Maibach, eds), pp. 239-55, CRC Press, Boca Raton, Fla., 
2005)). Microneedles have been shown to be painless in 
human subjects relative to hypodermic needles (Mikszta et 
al., Nat. Med. 8:415-19 (2002); Kaushik et al., Anesth Analg 
92:502-04 (2001 ). Unlike transdermal patches, microneedles 
also have been successfully used to deliver a variety of com-
pounds into the skin, including macromolecules. In vitro skin 
permeability enhancement of two to four orders of magnitude 
2 
has been observed for small molecules (e.g., calcein) and 
large compounds (e.g., proteins and nanoparticles) (Henry et 
al., J Pharm Sci 87:922-25 (1998); McAllister, et al., Proc 
Natl Acad Sci USA 100:13755-60 (2003)). In vivo delivery 
5 has been shown for peptides, such as insulin and desmo-
pressin (Martanto et al., Pharm. Res. 21:947-52 (2004); 
Cormier, et al., J Control Release 97:503-11 (2004)); genetic 
material, including plasmid DNA and oligonucleotides (Lin 
et al., Pharm. Res. 18: 1789-93 (2001 ); Chabri et al., Br J 
10 Dermatol 150:869-77 (2004)); and vaccines directed against 
hepatitis Band anthrax (Mikszta et al., Nat. Med. 8:415-19 
(2002); Mikszta et al., J Infect Dis 191 :278-88 (2005)). 
Four different modes ofmicroneedle-based drug delivery 
have been primarily investigated (Prausnitz, Adv Drug Deliv 
15 Rev 56:581-87 (2004); Prausnitz et al., Microneedles In Per-
cutaneous Penetration Enhancers (Smithand & Maibach, 
eds), pp. 239-55, CRC Press, Boca Raton, Fla., 2005). These 
modes are (1) piercing an array of solid microneedles into the 
skin followed by application of a drug patch at the treated site 
20 (Henry, J. Pharm. Sci. 87:922-25 (1998)); (2) coating drug 
onto microneedles and inserting them into the skin for sub-
sequent dissolution of the coated drug within the skin 
(Cormier et al., J Control Release 97:503-11 (2004)); (3) 
encapsulating drug within biodegradable, polymeric micron-
25 eedles followed by insertion into skin for controlled drug 
release (J-H Park, et al., Pharma. Res. 23:1008-19 (2006)); 
and ( 4) injecting drug through hollow microneedles (Zahn et 
al., Biomed Microdevices 2:295-303 (2000)). 
Among these approaches, coated microneedles are attrac-
30 tive for rapid bolus delivery of high molecular weight mol-
ecules into the skin, which can be implemented as a simple 
'Band-Aid' -like system for self-administration. Further-
more, storing a drug in a solid phase coating on microneedles 
may enhance long-term stability of the drug, even at room 
35 temperature. For instance, desmopressin coated onto micron-
eedles has been shown to maintain 98% integrity after six 
months storage under nitrogen at room temperature (Cormier 
et al., J Control Release 97:503-11 (2004)). Coated micron-
eedles are also particularly attractive for vaccine delivery to 
40 the skin, because antigens can be targeted to epidermal 
Langerhans cells and dermal dendritic cells for a more potent 
immune response. For example, a strong immune response 
against a model ovalbumin antigen delivered from coated 
microneedles has been shown in guinea pigs (Matriano et al., 
45 Pharm Res 19:63-70 (2002)). 
While the microneedle itself can be fabricated by adapting 
the tools of the microelectronics industry for inexpensive, 
mass production (Reed & Lye, Proc IEEE 92:56-75 (2004)), 
precise coating of microneedles presents technical chal-
50 lenges. Among the various conventional coating processes, 
such as dip coating, roll coating and spray coating (Bier-
wagen, Electrochim. 37:1471-78 (1992)), dip coating is par-
ticularly appealing for coating microneedles because of its 
apparent simplicity and ability to coat complex shapes. A 
55 conventional dip-coating process typically involves submerg-
ing and withdrawing an object from a coating solution, and 
then drying the continuous liquid film adhering to the surface 
of the object to yield a solid coating. However, such dip 
coating to coat microneedles by simply dipping and with-
60 drawing them from an aqueous solution of a compound (e.g., 
calcein, sulforhodamine or vitamin B) results in non-uniform 
coatings with frequent spreading of the solution to the sub-
strate from which the microneedles extend. Moreover, pre-
dictions of dip-coating theory to produce uniform coatings 
65 from different coating solutions mostly apply to static equi-
librium systems; dynamic systems as in the case of dip coat-
ing are more complex. In addition, because surface tension-
US 9,364,426 B2 
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driven phenomena often take place on the micron scale, 
conventional dip-coating methods have difficulty coating 
specified sections of micron-dimensioned structures, espe-
cially when those structures are closely spaced. For instance, 
bridging of liquid coating material between closely spaced 
microneedles is problematic. It therefore would be desirable 
to provide a micron-scale, dip coating process to coat micron-
eedles with uniform and spatially controlled coatings using 
methods suitable for a breadth of drugs and biopharmaceuti-
cals. 
4 
from the aperture. The physical mask may include a plurality 
of holes or slits which closely circumscribe each microneedle 
or a single row ofmicroneedles. The one or more reservoirs 
may be defined in a secondary structure, or the physical mask 
may have a plurality of the reservoirs defined therein. In one 
embodiment, the physical mask is in the form of a rigid plate 
secured to the reservoir. The coating liquid in the reservoir 
preferably is agitated or flowed to maintain composition uni-
formity. 
10 In one embodiment, the step of inserting the microneedle 
U.S. Pat. No. 6,855,372 to Trautman et al. discloses pro-
cesses and apparatus for coating skin-piercing microprojec-
tions, in which dipping is done by moving the microprojec-
tions tangentially across and through a thin film ofliquid on a 
rotating drum. Usefulness of the process would appear to be 15 
limited due to the tendency of ripple formation in the film 
while dipping microprojections. Ripples would cause liquid 
through the aligned aperture is done before moving both the 
physical mask and the microneedle in a manner to cause the 
microneedle to be dipped into the coating liquid. 
In another embodiment, the method further includes insert-
ing the at least one microneedle into the same or a different 
coating liquid and then removing the microneedle from said 
same or different coating liquid. to touch and coat the substrate that carries the microprojec-
tions or would cause differences in coating length of micro-
projections on the leading and trailing edge of the array. The 
method also would appear be restricted to certain dip lengths 
and to certainmicroprojection spacings, given that wicking of 
liquid up between closely spaced microprojections and onto 
the base of the device would still be expected to be a problem. 
It therefore would be desirable to provide microneedle coat-
ing processes that reduces or eliminates between-needle 
wicking and offers better coating uniformity and better con-
trol of dip/coating length on each microneedle. It would also 
be desirable to provide improved methods for precisely coat-
ing microneedles or other microstructures with a variety of 
materials, including materials other than homogeneous liquid 
solutions. 
SUMMARY OF THE INVENTION 
Coated microneedle devices and methods of making such 
devices are provided. In one aspect, a method for coating 
includes providing a microstructure having at least one sur-
face in need of coating; and applying a coating liquid, which 
comprises at least one drug, to the at least one surface of the 
microstructure, wherein the surface energy of the coating 
liquid is less than the surface energy of the surface of the 
microstructure. The method may further include precoating 
the at least one surface of the micro structure with a material to 
increase the surface energy of said surface, and/or modifying 
the coating liquid to decrease the surface tension of said 
coating liquid. The coating liquid may be aqueous, may 
include a viscosity enhancer and/or a surfactant. The method 
may include volatilizing at least a portion of a solvent, if used 
In another aspect, a microneedle device for insertion of a 
20 drug into a biological tissue is provided that includes at least 
one microneedle having a base, a tip end, and a shaft portion 
therebetween; and a coating on at least a portion of the surface 
of the at least one microneedle, the coating comprising at least 
one drug and a viscosity enhancer. The coating may further 
25 include a surfactant. The viscosity enhancer may include 
cellulose, a cellulose derivative, hyaluronic acid, xanthan 
gum, alginic acid, alginic acid derivative, polyvinylpyrolli-
done, acacia, guar gum, or a carbohydrate. The coating may 
have a heterogeneous composition, which may include dis-
30 crete particles, two or more discrete layers, or two or more 
different phases. The coating may include a hydro gel, and the 
hydrogel coating may be in a dried state or hydrated state. 
In one embodiment, all of the coating is adapted to come 
off of the microneedle following insertion into a biological 
35 tissue. For example, the coating may be adapted to come off 
of the microneedle in fifteen minutes or less following inser-
tion into a biological tissue. In one case, the coating com-
prises drug dispersed in a matrix material which provides 
controlled release of the drug. In another case, the drug is a 
40 hydrophobic molecule and the coating further comprises an 
amphiphilic material. 
In another embodiment, at least a portion of the coating is 
adapted to remain on the microneedle following insertion into 
a biological tissue. In still another embodiment, substantially 
45 all of the coating is adapted to remain on the microneedle, 
which may be a sensor, following insertion into a biological 
tissue. 
in the coating liquid, to form a solid coating. The coating 50 
liquid may comprises a molten material having a melting 
temperature greater than 25° C., which is then cooled to for a 
solid coating. In a preferred embodiment, the microstructure 
In another aspect, a microneedle device is provided for 
insertion of a drug into a biological tissue, which includes at 
least one microneedle having a base, a tip end, and a shaft 
portion therebetween; and a coating on at least a portion of the 
surface of the at least one microneedle, the coating compris-
ing at least one drug, wherein the coating has a heterogeneous 
composition. The coating may include discrete particles, two 
or more discrete layers, two different phases, or a combina-
tion thereof. 
is a single microneedle or an array of two or more micron-
eedles. In a preferred embodiment, a physical mask is utilized 55 
during application of the coating liquid to the micro structure. 
In one embodiment, a method for coating at least one 
microneedle includes the steps of providing a coating liquid 
disposed in one or more reservoirs, the coating liquid com-
prising at least one drug; providing a physical mask having 60 
one or more apertures, each aperture having cross-sectional 
dimensions larger than the at least one microneedle to be 
coated; aligning the at least one microneedle with at least one 
of the one or more apertures; inserting the at least one micron-
eedle through the aligned aperture and into the coating liquid, 65 
thereby coating at least a portion of the microneedle; and 
removing the coated microneedle from the coating liquid and 
In another aspect, a microneedle device for insertion of a 
drug into a biological tissue is provided which includes at 
least one microneedle having a base, a tip end, and a shaft 
portion therebetween; and a coating on at least a portion of the 
surface of the at least one microneedle, the coating compris-
ing at least one drug, wherein the shaft portion of the at least 
one microneedle comprises one or more pockets therein. The 
coating may be located substantially only in the one or more 
pockets. The one or more pockets may contain at least a 
portion of the coating where the coating is in the form of a 
liquid, gel, microparticles, or a combination thereof. 
US 9,364,426 B2 
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The at least one microneedle of these devices is formed of 
stainless steel, titanium, or another metal. In a preferred 
embodiment, the microneedles are electropolished. In pre-
ferred embodiments, the microneedle device includes two or 
more of the microneedles. The drug preferably is a therapeu-
tic, diagnostic, or prophylactic agent. 
In another aspect, a method is provided for making a 
microneedle device, which includes forming one or more 
microneedles from a metal; and electropolishing the one or 
more microneedles to smooth the surfaces of the micron- 10 
eedles. The step of forming may include laser cutting. 
In still another aspect, a microneedle patch is provided 
which includes an array two or more microneedles extending 
out of plane from a substrate; and an adhesive material dis-
posed between the two or more microneedles, the adhesive 15 
material comprising an adhesive suitable for removably 
securing the microneedle patch to a patient's skin. The adhe-
sive material may include a double-sided adhesive tape. It 
may be a pressure sensitive adhesive. In another embodiment, 
the adhesive material results from application of a liquid 20 
adhesive material to the substrate. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. lA is a cross-sectional view of one embodiment of an 25 
6 
using a physical mask to control deposition of coating, with 
mask having multiple closed dip holes built into the mask 
(FIG. lOA) or a single reservoir in fluid communication with 
open dip holes (FIG. lOB). 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Coated microneedle devices and methods of coating 
microneedles have been developed to produce microneedles 
and microneedle arrays having a variety of coatings improve-
ments, enabling a wide range of drug materials to be control-
lably coated onto microneedles and then delivered into bio-
logical tissues, particularly fortransdermal drug delivery. The 
methods provide for uniform coatings, for coatings of par-
ticles or other heterogeneous coatings. The microneedle 
shafts may include pockets for containing coating materials, 
particularly liquid, gel, and particle coatings. In a preferred 
embodiment, the microneedle coating includes a solid coat-
ing that contains or consists of at least one drug. The coated 
microneedles may be incorporated into a transdermal drug 
delivery patch or other drug delivery device. 
The coating process can reproducibly produce uniform, 
substantially continuous coatings on precise portions of the 
microneedles' shafts without bridging or patchiness, thereby 
providing enhanced dosage control in the manufacturing of 
drug coated microneedles. This is accomplished by various 
means of providing that the coating liquid precisely contacts 
the microneedle or selected portion thereof. In one embodi-
in-plane microneedle row-coating device showing the coat-
ing solution reservoir with the microneedle row aligned with 
the dip holes. FIG. lB is a perspective view of the in-plane 
microneedle row-coating device having x, y and z-micropo-
sitioners and a stereomicroscope objective. One embodiment 
of a coating device for coating an array of microneedles is 
shown in FIGS. lC-lE, which includes a first portion (FIG. 
30 ment, devices and methods have been developed to limit 
deposition of the coating to the microneedle. By avoiding 
deposition of the coatings onto the substrates having the 
microneedles, dosage control is improved and product loss 1 C) that includes a rectangular etched channel to hold coating 
solution, a feeding port, and alignment holes, and a second 
portion (FIG. lD) that includes a physical mask with dip 35 
holes apertures and alignment holes. FIG. lE shows a plan 
view of the two portions assembled. 
FIGS. 2A-2B show one embodiment ofindividual micron-
eedles imaged by a scanning electron microscope after clean-
ing with powdered detergent and after electropolishing, 
respectively. 
during coating is minimized. 
As used herein, the term "biological tissue" includes essen-
tially any cells, tissue, or organs, including the skin or parts 
thereof, mucosa! tissues, vascular tissues, lymphatic vessels, 
ocular tissues (e.g., cornea, conjunctiva, sclera), and cell 
membranes. The biological tissue can be in humans or other 
40 types of animals (particularly mammals), as well as in plants, 
insects, or other organisms, including bacteria, yeast, fungi, 
and embryos. Human skin and sclera are biological tissues of 
particular use with the present microneedle devices and meth-
ods of use thereof. 
FIGS. 3A-3D are scanning electron microscope images 
showing different microneedle geometries including differ-
ent lengths and widths with a tip angle of 55°, pockets of 
different shapes and sizes in microneedles, and different 45 
grooved surfaces, respectively in FIGS. 3A-C, and an out-of-
plane array (FIG. 3D). 
As used herein, the terms "comprise," "comprising," 
"include," and "including" are intended to be open, non-
limiting terms, unless the contrary is expressly indicated. 
Coated-Microneedle Devices FIGS. 4A-4B show examples of microneedles having good 
coating results using brightfield microscopy using a vitamin 
B coating solution. FIG. 4C shows various embodiments of 50 
microneedles having different coating lengths. 
In one aspect, a microneedle device is provided for inser-
tion of a drug into a biological tissue. In a preferred embodi-
ment, the device includes at least one microneedle having a 
base, a tip end, and a shaft portion therebetween, and a coating 
on at least a portion of the surface of the microneedle, wherein 
the coating comprises a drug and a viscosity enhancer. 
FIGS. SA-SG show a variety of molecules and particles 
coated onto certain embodiments of single microneedles as 
seen using fluorescence or brightfield microscopy. 
FIGS. 6A-6F show the effect of the surface tension and 55 In another aspect, a microneedle device is provided which 
viscosity of different coating formulations on microneedle 
coating uniformity. 
FIGS. 7A-7B are graphs indicating the mass of vitamin B 
coated on different microneedles in various embodiments. 
FIGS. SA-SB illustrate one embodiment of a process for 
assembling a microneedle patch including coated in-plane 
microneedle rows as described herein. 
FIGS. 9A-9B illustrate another embodiment of a process 
for assembling a microneedle patch including coated out-of-
plane microneedle arrays as described herein. 
FIGS. lOA-lOB are cross-sectional views of microneedles 
in a microneedle array which are dipped into a coating liquid 
includes at least one microneedle having a base, a tip end, and 
a shaft portion therebetween, and a coating on at least a 
portion of the surface of the microneedle, wherein the coating 
includes at least one drug and is a heterogeneous composi-
60 tion. For instance, the coating may have discrete particles, 
two or more discrete layers, two different phases, or a com-
bination thereof. The drug may be in the particles, one or 
more of the layers, or one or more of the different phases. 
In yet another aspect, a microneedle device is provided 
65 which includes at least one microneedle having a base, a tip 
end, and a shaft portion therebetween, and a coating on at 
least a portion of the surface of the microneedle, wherein the 
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coating includes at least one drug and the shaft portion of the 
microneedle has one or more pockets therein. 
Microneedles 
The microneedle can be formed/constructed of different 
biocompatible materials, including metals, glasses, semi-
conductor materials, ceramics, or polymers. Examples of 
suitable metals include pharmaceutical grade stainless steel, 
gold, titanium, nickel, iron, tin, chromium, copper, and alloys 
thereof. In one embodiment, stainless steel is an attractive 
material for microneedle fabrication because it is FDA 
approved for medical devices and is inexpensive. 
In another embodiment, the microneedle may include or be 
formed of a polymer. The polymer can be biodegradable or 
non-biodegradable. Examples of suitable biocompatible, bio-
degradable polymers include polylactides, polyglycolides, 
polylactide-co-glycolides (PLGA), polyanhydrides, poly-
orthoesters, polyetheresters, polycaprolactones, polyestera-
mides, poly(butyric acid), poly(valeric acid), polyurethanes 
and copolymers and blends thereof. Representative non-bio-
degradable polymers include polyacrylates, polymers of eth-
ylene-vinyl acetates and other acyl substituted cellulose 
acetates, non-degradable polyurethanes, polystyrenes, poly-
vinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), 
chlorosulphonate polyolefins, polyethylene oxide, blends 
and copolymers thereof. Biodegradable microneedles can 
provide an increased level of safety compared to non-biode-
gradable ones, such that they are essentially harmless even if 
inadvertently broken off into the biological tissue. This 
applies whether the microneedles contain molecules for 
delivery or serve merely as vehicle for transporting a drug 
coating. 
8 
(base) portion that would remain uninserted. The cross-sec-
tion, or width, is tailored to provide, among other things, the 
mechanical strength to remain intact for the delivery of the 
drug or for serving as a conduit for the withdrawal of biologi-
cal fluid, while being inserted into the skin, while remaining 
in place during its functional period, and while being 
removed (unless designed to break off, dissolve, or otherwise 
not be removed). In various embodiments, the microneedle 
may have a length of between about 50 µm and about 5000 
10 µm, preferably between about 100 µm and about 1500 µm, 
and more preferably between about 200 µm and about 1000 
µm. In one embodiment, the length of the microneedle is 
about 750 µm. In various embodiments, the base portion of 
the microneedle has a width or cross-sectional dimension 
15 between about 20 µm and about 500 µm, preferably between 
about 50 µm and about 350 µm, more preferably between 
about 100 µm and 250 µm. For a hollow microneedle, the 
outer diameter or width may be between about 50 µm and 
about 400 µm, with an aperture diameter of between about 5 
20 µm and about 100 µm. The microneedle may be fabricated to 
have an aspect ratio (width:length) between about 1:1 and 
1: 10. Other lengths, widths, and aspect ratios are envisioned. 
In a preferred embodiment, the microneedle includes one 
or more pockets. As used herein, the term "pocket" refers to 
25 an aperture extending crosswise into the microneedle shaft 
(e.g., perpendicular to the direction of microneedle move-
ment during the process of insertion into biological tissue). 
The pocket preferably extends through the shaft, but it is 
envisioned that it alternatively may be closed at one end, 
30 distal the opening in the shaft. This is distinct from a hollow 
bore wherein a concentric space extends substantially 
through the axial length of the shaft. As used herein, the 
pockets are considered to be part of the surface of the micron-
eedle. The pocket preferably contains coating material, which 
In one embodiment, the microneedle device includes a 
substantially planar foundation from which one or more 
microneedles extend, typically in a direction normal (i.e., 
perpendicular or 'out-of-plane') to the foundation. Alterna-
tively, microneedles may be fabricated on the edge of a sub-
strate 'in-plane' with the substrate. In another embodiment, a 
single microneedle can be fabricated on a substrate surface or 
edge. In one embodiment, microneedles are fabricated on a 
flexible base substrate. It would be advantageous in some 
circumstances to have a base substrate that can bend to con-
form to the shape of the tissue surface. In another preferred 
embodiment, the microneedles are fabricated on a curved 
base substrate. The curvature of the base substrate typically 
would be designed to conform to the shape of the tissue 45 
surface. 
35 may be particularly advantageous in certain embodiments 
where the coating material needs to be protected from 
mechanical forces during the insertion process, e.g., when the 
coating comprises a liquid or particles. It has been found that 
such coating materials are more likely than others to be pre-
40 maturely dislodged or wiped off of the microneedle during 
insertion into skin, diminishing the complete delivery of the 
complete dosage of the coating. However, the pockets of the 
microneedles advantageously function to shield the coating 
material therein from the mechanical forces of insertion. The 
pockets may be made in various shapes (e.g., circular, square, 
rectangular) and of various numbers and dimensions and 
different spacings within the microneedle. The microneedles may be solid or hollow. The micron-
eedles can be porous or non-porous. The microneedles may 
be planar, cylindrical, or conical. The microneedles can have 
a straight or tapered shaft. In one embodiment, the diameterof 50 
the microneedle is greatest at the base end of the microneedle 
and tapers to a point at the end distal the base. The micron-
eedles can also be fabricated to have a shaft that includes both 
a straight (i.e., untapered) portion and a tapered portion. The 
microneedles can be formed with shafts that have a circular 55 
cross-section in the perpendicular, or the cross-section can be 
non-circular. 
The tip portion of the microneedles can have a variety of 
configurations. The tip of the microneedle can be symmetri-
cal or asymmetrical about the longitudinal axis of the shaft. 60 
The tips may be beveled, tapered, squared-off, or rounded. 
The tip portion generally has a length that is less than 50% of 
the total length of the microneedle. 
In various embodiments, the microneedle device includes a 
single microneedle or an array of two or more microneedles. 
The microneedles can be fabricated as, or combined to form 
microneedle arrays. For example, the device may include an 
array of between 2 and 1000 (e.g., between 2 and 100) 
microneedles. In one embodiment, a device may include 
between 2 and 10 microneedles. An array of microneedles 
may include a mixture of different microneedles. For 
instance, an array may include microneedles having various 
lengths, base portion diameters, tip portion shapes, spacings 
between microneedles, drug coatings, etc. 
Fabrication of Microneedles 
The microneedle can be fabricated by a variety of methods 
known in the art or as described in the Examples below. 
Details of possible manufacturing techniques are described, 
for example, in U.S. PatentApplicationPublicationNo. 2006/ 
0086689 Al to Raju et al., U.S. Patent Application Publica-The dimensions of the microneedle, or array thereof, are 
designed for the particular way in which it is to be used. The 
length typically is selected taking into account both the por-
tion that would be inserted into the biological tissue and the 
65 tion No. 2006/0084942 to Kim et al., U.S. Patent Application 
Publication No. 2005/0209565 to Yuzhakov et al., U.S. Patent 
Application Publication No. 2002/0082543 Al to Park et al., 
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U.S. Pat. No. 6,334,856 to Allen et al., U.S. Pat. No. 6,611, 
707 to Prausnitz et al., U.S. Pat. No. 6,743,211 to Prausnitz et 
al., all of which are incorporated herein by reference. 
In a preferred embodiment, the microneedles are cut from 
stainless steel or other metal sheets using a laser (e.g., an 
infrared laser) or other techniques known in the art. Micron-
eedles of different lengths and widths from sheets up to 125 
µm have been successfully fabricated by this method. 
In a preferred embodiment, an electropolishing technique 
is used to produce clean, smooth, and sharp microneedle 
surfaces. Electropolishing can remove slag deposits from the 
microneedles, as laser-cutting of metals such as stainless steel 
may produce microneedles with rough edges covered with 
slag deposits. In one non-limiting embodiment, laser cut 
stainless steel microneedles can be electropolished in a solu-
tion that includes glycerin, ortho-phosphoric acid (85% ), and 
water in a ratio of 6:3: 1 by volume. In one example, a copper 
plate is used as the cathode and the metal microneedles serve 
as the anode. The anode may be vibrated using means known 
in the art to help remove gas bubbles generated at the anodic 
surface during electropolishing. Electropolishing is believed 
to be especially effective, because current density (i.e., etch-
ing rate) is largest at sites of high curvature, which inherently 
targets sites of surface roughness for removal. In some 
embodiments, the electropolishing process has an output rate 
of finished microneedle arrays of one 50-needle array every 
30 minutes using a single laser. This rate can be increased by 
process optimization and use of multiple lasers. 
Coating/Drug Formulation 
The microneedles include at least one drug-containing 
coating over at least part of the surface of the microneedle. In 
a preferred embodiment, the coating is applied in a manner 
such that the surface energy (or surface tension) of the coating 
liquid is less than the surface energy of the microneedle. This 
facilitates effective coating of the microneedle. As detailed 
herein, this surface energy differential may be achieved by 
modifying the coating liquid, modifying the microneedle sur-
face properties, or a combination of such modifications. 
In one aspect, the microneedle coating may be a heteroge-
neous composition. For example, the coating may include 
two or more phases (e.g., solid/liquid, solid/solid, emulsion, 
gel) two or more discrete layers, discrete particles, or a com-
bination thereof. In one embodiment, the microneedle 
includes one or more pockets which are coated to contain a 
drug formulation which is in the form of a liquid, gel, par-
ticles, or a combination thereof. 
The coating may consist of only the one or more drugs or it 
may include one or more non-volatile components (i.e., the 
components remaining after the solvent of the coating liquid 
has been volatilized) to modify the surface energy properties 
of the coating, to modify release characteristics of the drug, or 
to do both. Components may also be added to improved 
adhesion of wet or dry coating to the microneedle. Such 
non-volatile components are described below in discussing 
the coating liquid. 
10 
the drug is a hydrophobic molecule and the coating further 
comprises an amphiphilic material, which facilitates dissolu-
tion/release of the coating from the microneedle. 
In another embodiment, the coating is adapted for slow 
release (e.g., dissolution) when inserted into a biological 
tissue. Slow dissolution is more than 15 minutes, and may 
range, for example, from a few hours to a day or two, or a 
week. This embodiment would be particularly useful to 
deliver clonidine (e.g., to treat hypertension), testosterone 
10 (e.g., for replacement therapy), insulin (e.g., for basal diabetic 
therapy), and other drugs suitable for long-term therapy, par-
ticularly drugs with relatively narrow therapeutic windows. 
In still another embodiment, the coating comprises a material 
which is substantially insoluble when inserted into a biologi-
15 cal tissue. 
In one embodiment, at least a portion of the coating is 
adapted to remain on the microneedle following insertion into 
a biological tissue. For example, the coating may include a 
matrix material or layer that serves to modulate release of a 
20 drug, which may be dispersed therein, which may be located 
in an underlying layer, or both. 
In still another embodiment, all or substantially all of the 
coating is adapted to remain on the microneedle following 
insertion into a biological tissue. For example, the micron-
25 eedle may be part of a sensor, and the coating material may aid 
in operation of the sensor without being released. 
In one embodiment, the coating may include a plurality of 
discrete microparticles or other particles. The coating may 
consist only of these particles, packed together to form a 
30 coating once the solvent of the coating liquid has been vola-
tilized. Alternatively, these particles may be dispersed within 
a continuous matrix material. Examples of the particles or 
microparticles that may form part or all of the coating include 
solid or gel-like organic or inorganic compounds in a non-
35 dissolving solvent (e.g., barium sulfate suspension in water), 
liposomes, proteins, cells, virus particles, prions, and combi-
nations thereof. In one case, drug molecules are incorporated 
into a microparticle or nanoparticles form. As used herein, the 
term "microparticle" encompasses microspheres, microcap-
40 sules, microparticles, and beads, having a number average 
diameter of 1 to 100 µm, most preferably 1 to 25 µm. The term 
"nanoparticles" are particles having a number average diam-
eter of 1 to 1000 nm. Microparticles may or may not be 
spherical in shape. "Microcapsules" are defined as micropar-
45 ticles having an outer shell surrounding a core of another 
material, in this case, drug. The core can be liquid, gel, solid, 
gas, or a combination thereof "Microspheres" can be solid 
spheres, can be porous and include a sponge-like or honey-
comb structure formed by pores or voids in a matrix material 
50 or shell, or can include multiple discrete voids in a matrix 
material or shell. The microparticle or nanoparticles may 
further include a matrix material. The shell or matrix material 
may be a polymer, amino acid, saccharide, or other material 
known in the art of microencapsulation. 
55 
In one embodiment, all of the coating is adapted to come 
off of the microneedle following insertion into a biological 
tissue. In a preferred embodiment, the coating is adapted to 
come off of the microneedle rapidly. Rapid dissolution is 
equal to or less than 15 minutes, preferably less than 5 min- 60 
utes, more preferably less than 5 minutes, and more prefer-
ably less than 10 sec. This embodiment would be particularly 
useful to deliver vaccines, local anesthetics (e.g., lidocaine ), 
cosmetic formulations (e.g., botox, tattoos), and drugs suit-
able for bolus delivery. In one case, the coating comprises 65 
drug dispersed in a matrix material (e.g., microencapsulated) 
which provides controlled release of the drug. In another case, 
In another embodiment, the microneedle coating includes 
multiple, discrete (distinct) layers. This may be achieved, for 
example, by using multiple dipping and drying steps, into the 
same or different coating liquids. 
In a preferred embodiment, the microneedle is first coated 
with a precoat material, which is disposed between at least a 
portion of the at least one microneedle and the coating which 
comprises the drug. Such a precoat material preferably is used 
to alter or improve the surface properties (e.g., hydrophilicity 
or hydrophobicity) of the microneedle surface to enhance 
adhesion and uniformity of the drug-containing coating. The 
use of a precoat may enable one to omit surfactant from the 
primary, drug-containing coating liquid. The precoat may be 
US 9,364,426 B2 
11 
substantially soluble or insoluble in vivo. In non-limiting 
examples, the precoat may consist of silicon dioxide or a 
biocompatible polyester, polyethylene glycol (PEG), PLGA 
or polyanhydride. Deposition of silicon dioxide or other pre-
coat material may be achieved using vapor deposition or other 
techniques known in the art. 
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cromoglycate ), local anesthetics (e.g., amethocaine, 
lignocaine, oxbuprocaine, proxymetacaine ), cyclosporine, 
diclofenac, urogastrone and growth factors such as epidermal 
growth factor, mydriatics and cycloplegics, mitomycin C, and 
collagenase inhibitors. 
Coating Methods 
In still other embodiments, an exterior, secondary coating 
may be used to alter release kinetics of a drug from an under-
lying coating layer. For example, the exterior coating may 
include a material known in the art that dissolves or biode-
grades relatively solely in vivo to provide delayed or slow 
release of drug. In one example, the exterior coating could 
include a hydrogel or other water swellable material to pro-
vide controlled drug release. In another variation, an exterior 
layer could provide for rapid (e.g., bolus) release of drug. An 
underlying layer could provide bolus or controlled release of 
the same or another drug. 
Methods have been developed for coating microneedles. It 
also is envisioned that the present coating methods and 
devices can be used or readily adapted to coat other micro-
lO structures, particularly structures having micron-scale 
dimensions where surface tension issues impact coating loca-
tion, coating thickness, and coating processibility. Represen-
tative examples of other micro structures include microfluidic 
15 devices, microarrays, microelectrodes, AFM probes, 
microporous materials, microactuators, microsensors, and 
the like. 
The Coating Liquid 
The coating liquid is the material applied to coat the one or 
Optionally, additional drug can be integrated into the 
microneedle structure, passed through bores or channels in 
the microneedle, or a combination thereof. 20 more microneedles. The coating liquid includes the coating/ 
drug formulation material(s) described above that ultimately 
intended to serve as the microneedle coating. As used herein, 
the term "coating liquid" includes pure solutions, suspen-
A wide range of drugs may be formulated for delivery with 
the present microneedle devices and methods. As used herein, 
the terms "drug" or "drug formulation" are used broadly to 
refer to any prophylactic, therapeutic, or diagnostic agent, or 
other substance that may be suitable for introduction to bio- 25 
logical tissues, including pharmaceutical excipients and sub-
stances for tattooing, cosmetics, and the like. The drug can be 
a substance having biological activity. The drug formulation 
may include various forms, such as liquids, liquid solutions, 
gels, hydro gels, solid particles (e.g., microparticles, nanopar- 30 
ticles), or combinations thereof. The drug may comprise 
small molecules, large (i.e., macro-) molecules, or a combi-
nation thereof. In a preferred embodiment, the drug formula-
tion is solid at ambient temperatures so that the coating on the 
microneedle is solid. A solid coating may increase the shelf 35 
life of certain active agents and can provide better ease of 
handling of the coated microneedles. 
In representative, non-limiting, embodiments, the drug can 
be selected from among amino acids, vaccines, antiviral 
agents, DNA/RNA, gene delivery vectors, interleukin inhibi- 40 
tors, immunomodulators, neurotropic factors, neuroprotec-
tive agents, antineoplastic agents, chemotherapeutic agents, 
polysaccharides, anti-coagulants, antibiotics, analgesic 
agents, anesthetics, antihistamines, anti-inflammatory 
agents, and vitamins. The drug may be selected from suitable 45 
proteins, peptides and fragments thereof, which can be natu-
rally occurring, synthesized or recombinantly produced. In 
one embodiment, the drug formulation includes insulin. 
A variety of other pharmaceutical agents known in the art 
may be formulated for administration via the microneedle 50 
devices described herein. Examples include ~-adrenoceptor 
antagonists (e.g., carteolol, cetamolol, betaxolol, 
levobunolol, metipranolol, timolol), miotics (e.g., pilo-
carpine, carbachol, physostigmine ), sympathomimetics (e.g., 
adrenaline, dipivefrine ), carbonic anhydrase inhibitors (e.g., 55 
acetazolamide, dorzolamide ), prostaglandins, anti-microbial 
compounds, including anti-bacterials and anti-fungals (e.g., 
chloramphenicol, chlortetracycline, ciprofloxacin, framyce-
tin, fusidic acid, gentamicin, neomycin, norfloxacin, ofloxa-
cin, polymyxin, propamidine, tetracycline, tobramycin, 60 
quinolines), anti-viral compounds (e.g., acyclovir, cidofovir, 
idoxuridine, interferons), al dose reductase inhibitors, anti-
inflammatory and/or anti-allergy compounds (e.g., steroidal 
compounds such as betamethasone, clobetasone, dexametha-
sone, fluorometholone, hydrocortisone, prednisolone and 65 
non-steroidal compounds such as antazoline, bromfenac, 
diclofenac, indomethacin, lodoxamide, saprofen, sodium 
sions (e.g., solid particles-dispersed-in-liquid), emulsions, 
and combinations thereof, as well as molten materials. The 
molten material may be the active drug or it may act as the 
dissolving or suspending medium for the drug and/or addi-
tives or particles or a combination thereof. It is essentially any 
non-gas material or combination of materials having a vis-
cosity suitable for use in a coating process to coat micron-
eedles. The coating liquid may be homogeneous or heteroge-
neous. In a preferred embodiment, the coating liquid is 
aqueous. In one embodiment, the coating liquid comprises 
particles suspended in a solvent. 
The surface energy (or surface tension) of the coating liq-
uid preferably is less than the surface energy of the micron-
eedle. Depending on the drug, and the solvent if any, the 
coating liquid may need to include one or more additives to 
alter the surface energy of the coating liquid. For example, the 
surface energy of stainless steel is 53.3 mN/m and the surface 
energy of water is 72.8 mN/m. Therefore, an aqueous coating 
solution may need to include one or more additives to reduce 
the surface tension of the coating solution to less than 53 .3 
mN/m-preferably while increasing the viscosity of the coat-
ing solution so that thicker rather than thin coatings will be 
formed. 
Representative examples of additives include viscosity 
modifiers, surfactants, pH modifiers, diluents, or other phar-
maceutically acceptable excipients known in the art. Such 
additives preferably are water soluble, FDA approved as 
injectable excipients (for safety), solid at room temperature 
(to convert into a solid phase upon drying), and possess high 
surfactant or viscosity enhancement activity per unit mass (to 
provide minimal usage of additives and thereby increase drug 
percentage in the dry coatings). 
The coating liquid may include a solvent. As used herein, 
the term "solvent" is used generically and broadly to refer to 
any volatile component in the coating liquid, whether solvent 
or non-solvent for the drug in the coating liquid. The solvent 
is the component, if any, in the coating liquid that is volatil-
ized (e.g., evaporates) during/following application of the 
coating liquid onto the microneedle, thereby causing the non-
volatile coating materials to solidify and adhere to the 
microneedle. The solvent may be aqueous, organic, inor-
ganic, or a combination thereof. Representative examples of 
the suitable solvents include water, ethanol, ethyl acetate, 
isopropanol, propylene glycol, and benzyl alcohol. 
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In a preferred embodiment, the coating liquid includes one In another embodiment, the coating liquid is free of excipi-
ents all together. For instance, some drugs can remain stable 
at their melting point, and microneedles can be coated by 
dipping them into molten drug and then allowing the drug to 
cool and solidify, thereby forming the coating. In one embodi-
ment, the coating liquid comprises a molten material having a 
melting temperature greater than 25° C. Such embodiments 
advantageously enable delivery of pure drug and provide high 
drug mass loading per microneedle. An example of a suitable 
10 drug for use in this coating method is lidocaine, clonidine, and 
the like. 
or more surfactants in an amount/concentration effective to 
spread the coating liquid onto the microneedle and a viscosity 
enhancer in an amount/concentration effective to produce a 
coating having a desired thickness. For example, the thick-
ness desired is determined, in part, by the dosage of drug 
needed per microneedle, the surface area of the microneedle 
expected to penetrate the biological tissue, and the number of 
microneedles per array. Examples of suitable surfactants 
include nonionic surfactants, such as Poloxamers (e.g., Lutrol 
F-68) and polyoxyethylene sorbitan fatty acid esters (e.g., 
Tween 20). Examples of suitable viscosity enhancers include 
cellulose and derivatives thereof (e.g., sodium salt of car-
boxymethylcellulose (low viscosity), hydroxylpropyl cellu-
lose) hyaluronic acid, xanthan gum, alginic acid and deriva- 15 
tives thereof (e.g., sodium alginate, propylene glycol 
alginate), polyvinylpyrollidone, acacia, guar gum, or carbo-
hydrates such as sucrose or maltose. The concentrations of 
these additives in the coating liquid may range from 0.1 % to 
70% (weight/volume %). In one embodiment, the coating 20 
liquid comprises a drug, 1 % carboxymethylcellulose, an 
0.5% Lutrol F-68 NF. It is understood, however, that the 
particular additives and concentrations chosen for each for-
mulation will depend, in part, upon the coating requirements 
Apart from molten liquid existing in a pure liquid state, 
multi-component molten coating also may be formulated. 
Multi-component molten coating liquids generally consist of 
a dissolving medium created by heating a solid above its 
melting point to form a liquid state, into which a drug is 
dissolved. For example, PEG (MW 1500) may be heated to 
55° C. and then dexamethasone dissolved into it. The dissolv-
ing medium may be hydrophilic or hydrophobic. Represen-
tative examples of hydrophilic dissolving medium include to 
polyethylene glycols (PEGs) (melting point greater than 25° 
C.), sugars (especially low melting-point sugars such as xyli-
tol (melting point 92-96° C.), dextrose (melting point 146-
1500 C.), maltose (melting point 102° C.), and sorbitol (melt-
ing point 110-112° C.), water soluble polyoxyethylene 
derivatives (e.g., Brijs, Brij 72, melting point 44-45° C.), 
as well as any interaction among the particular drug and the 25 
additives selected. 
Anionic, cationic or nonionic surfactants can be used. Rep-
resentative examples and concentration ranges of anionic 
surfactants include docusate sodium (e.g., 0.01 % to 1 % 
wt/vol%) and sodium lauryl sulfate (e.g., 0.1%to3% wt/vol 
%). A representative example and concentration range of a 
cationic surfactant includes benzalkonium chloride (e.g., 
0.01% to 1% wt/vol%). Representative examples and con-
centration ranges of nonionic surfactants include polyoxyeth-
ylene sorbitan fatty acid esters (e.g., polysorbates 20, 40 and 
60 at 0.1%to3% wt/wt%), sorbitanfatty acid esters (0.1 % to 
3% wt/wt%), poloxamers (e.g. Lutrol F68 0.1 % to 5% wt/vol 
%), and polyoxyethylene alkyl ethers (0.05% to 1% wt/vol 
%). 
Certain drugs and certain coating liquids can be effectively 
and uniformly coated onto the microneedles without the need 
for surfactants or without the need for any additives. In one 
embodiment, certain hydrophobic drugs can be coated onto 
microneedles for quick release (e.g., between one and ten 
minutes) in vivo, where the coating liquid includes an 
amphiphilic viscosity enhancer without surfactant. Examples 
of suitable hydrophobic drugs include doxyrubicin, estradiol, 
testosterone, fentanyl, clonidine, oxybutynin, dexametha-
sone, indomethacin, and the like. 
In one embodiment, the process is used where the surface 
energy of the coating liquid is less than the surface energy of 
the microneedle (either the material of construction or after 
surface modification). In an alternative embodiment, the coat-
ing liquid may have surface energy greater than the micron-
eedle. This coating liquid will enable filling and coating of 
pockets in the microneedle surface without coating the 
remainder of the microneedle surface. The coating liquid may 
contain dissolved solid additives or drugs, or maybe devoid of 
any dissolved solids with even the drug being liquid at room 
temperature. In either case, the result will be a pocket filled 
with a solid (after drying) or a liquid phase, respectively. 
Particles may additionally be introduced into either of these 
formulations causing particles to be filled into the pockets. 
Relatively slow speeds of microneedle withdrawal, on the 
order of more than a second, from the microneedle immersed 
state to outside the coating liquid, have been found to be 
useful to facilitate the coating of only the pockets. 
polyethylene-propylene glycol copolymers (Poloxamers, 
e.g., Pluronic F-68, melting point 52° C.), poly(ethyleneox-
ide) (PEO) derivatives, PEG derivatives, PEG-PEO deriva-
30 tives, or various combinations thereof. Representative 
examples of hydrophobic dissolving media include to glyc-
eryl monostearate (melting point 55-60° C.), glyceryl palmi-
tostearate (melting point 52-55° C.), cetyl alcohol (melting 
point 56° C.), stearyl alcohol (melting point 56-60° C.), bees 
35 wax (melting point 56-60° C.) and other wax and combina-
tions thereof. Additives other than drugs may be included as 
dissolvable solids or liquid to the molten liquid coating solu-
tion to alter or improve the surface energy or viscosity of the 
molten coating liquid. Molten liquid coating liquids provide 
40 an alternative to solvent-based coating solutions to help sat-
isfy surface energy or viscosity or other physicochemical 
properties required for a particular coating application. 
Dip Coating Method and Apparatus 
In one aspect, a method is provided for coating a micro-
45 structure, which method includes providing a microstructure 
having at least one surface in need of coating, and applying a 
coating liquid, which comprises at least one drug, to the at 
least one surface of the microstructure, wherein the surface 
energy of the coating liquid preferably is less than the surface 
50 energy of the surface of the microstructure. In one case, this 
method includes precoating the at least one surface of the 
microstructure with a material to increase the surface energy 
of said surface, or otherwise modifying the surface energy 
properties of the microneedle. In another case, the method 
55 includes modifying the coating liquid to decrease the surface 
tension of the coating liquid. In preferred embodiments, the 
microstructure comprises at least one microneedle. 
In another aspect, a method is provided for coating at least 
one microneedle, which method includes the steps of (i) 
60 providing a coating liquid disposed in a reservoir, the coating 
liquid comprising at least one drug; (ii) providing a physical 
mask having one or more apertures therethrough, each aper-
ture having cross-sectional dimensions larger than the at least 
one microneedle to be coated; (iii) aligning the at least one 
65 microneedle with at least one of the one or more aperture; (iv) 
inserting the at least one microneedle through the aligned 
aperture; (v) inserting the at least one microneedle into the 
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coating liquid, thereby coating at least a portion of the 
microneedle; and (vi) removing the coated microneedle from 
the coating liquid and from the aperture. The one or more 
reservoirs may be defined in a secondary structure or the 
physical may have a plurality of the reservoirs defined in the 
physical mask. 
Steps (iv) and (v) can be done in two discrete steps or in a 
single step. For example, the step ofinserting the microneedle 
through the aligned aperture may be done before moving the 
physically masked microneedles to cause the microneedle to 
be dipped into the coating liquid; alternatively, the physical 
mask can be in a fixed position relative to the reservoir of 
coating liquid, so that only the microneedles are moved. 
By utilization of a physical mask, access of the coating 
liquid is restricted only to the microneedle shaft, thereby 
preventing contamination of the substrate from which the 
microneedles extend. That is, any meniscus rise or capillary 
action that may cause contact of the coating liquid to an 
adjacent microneedle or with the substrate is advantageously 
avoided such thatthe coating is on a majority of the surface of 
the shaft and the base substrate is free of the coating. For 
example, in embodiments, the coating is on 50% to 100% of 
the surface of the microneedle or on 75% to 100% of the 
surface of the microneedle. Furthermore, this "micro-dip 
coating" process is particularly advantageous for use with 
relatively smaller coating liquid volumes, such as might the 
case when coating microneedles with highly potent or expen-
sive substances, such as DNA/RNA. 
In a preferred embodiment, the physical mask is in the form 
of a plate having a one or more discrete apertures there-
through. These apertures preferably are the form of one or 
more holes or slits which closely circumscribe each micron-
eedle or a single row of microneedles. As used herein, the 
term "closely circumscribe" means that the physical mask is 
effective to restrain, by surface tension forces, the coating 
liquid to the reservoir and apertures, preventing it from 
"climbing up" the microneedle shaft substantially beyond the 
dipped portion of the microneedle which it is desired to coat. 
Surface energy properties of the coating system (physical 
mask, microneedle, and coating fluid) and operating condi-
tions (e.g., temperature, dipping/withdrawal speed) impact 
the selection ofappropriate dimensions for the holes and slits. 
16 
coating liquid is filled in these apertures from the open top. 
These can be periodically or continually refilled to maintain a 
constant amount of coating liquid in the reservoir. 
To reduce propensity of air bubbles in the reservoir and/or 
apertures in the plate, the device may include vent holes 
designed to release entrapped air. To prevent evaporation of 
coating liquid (or solvent thereof) from the coating liquid, a 
pumping device (e.g., an automated or manually pulsated 
syringe plunger) can be included with the coating apparatus 
10 to fill the coating liquid reservoir and to oscillate/mix the 
coating liquid in dip-coating holes. The coating liquid in the 
reservoir may be flowed or agitated to facilitate maintenance 
of a uniform coating liquid composition during the dipping 
process. Alternatively or in addition, the coating process may 
15 be performed at a reduced temperature (relative to ambient) to 
reduce the rate of evaporation of the coating liquid or solvent 
portion thereof. 
In one embodiment, the method further includes the step of 
volatilizing at least a portion of the solvent to form a solid 
20 coating. This may be referred to as "drying" the coating or 
coating liquid. A similar step may be included when using 
molten coating liquids, wherein the coated liquid is permitted 
to (or actively caused to) cool the molten material sufficiently 
to cause it to solidify, forming a solid coating on at least a 
25 portion of the microneedle. 
The coating method may further includes inserting the at 
least one microneedle into the same or a different coating 
liquid and then removing the microneedle from said same or 
different coating liquid. The composition of the coating liquid 
30 may include a solvent to dissolve part of the previous coating, 
if desired. In another embodiment, the method may further 
include the step of applying a second coating liquid onto the 
solid coating or onto a second surface of the microneedle in 
need of coating. The composition of the second coating liquid 
35 may include a second drug. Multiple such dippings into the 
same or a different coating liquid may be repeated. 
The process optionally may include an intervening dip into 
a cleaning solvent, e.g., to thin or remove part of a prior 
coating layer. This may be useful to build complete coating 
40 structures, e.g., where one coating composition is located on 
one part of the microneedle (e.g., a first pocket) and a second 
coating composition is located on another part of the micron-
eedle (e.g., a second pocket). In one embodiment, the physical mask is in the form of a 
substantially rigid plate secured to the reservoir (see e.g., FIG. 
lOA). The plate includes an array of micron-sized holes cor-
responding to the microneedles in a microneedle array to be 
coated. When properly aligned, for example using micropo-
sitioners or pre-aligned parts moving on a rail, each of the 
microneedles can be simultaneously inserted through the 
micron sized holes and into the coating liquid, resulting in a 50 
controlled micro-dip-coating process. The use of one or more 
micropositioners can be used to provide control over the 
microneedle length being coated, that is how much of the 
microneedle length is actually coated. Physical stops in the 
form of think sheets or protruding cylinders in between the 55 
physical mask and microneedles may also be used to control 
the microneedle length being coated. The coating device can 
While the present coating method using a physical mask 
45 has been described as applied to coat microneedles, it is 
envisioned that the process could be used or readily adapted 
to coat other microprotrusion type structures in other micro-
structures. 
Coating Process Considerations 
Based on thermodynamics, to obtain uniform coatings on 
microneedle surfaces, generally the surface tension of the 
coating liquid should be lower than the surface energy of the 
microneedle surface material (material of construction or 
overcoat deposition). A slow (taking more than a second) or 
rapid (taking less than a second or more preferably less than 
a tenth of a second or more preferably less than a hundredth of 
a second) withdrawal of the microneedle from the immersed 
state to outside the coating liquid will provide a uniform 
coating on the microneedle. Addition of a viscosity enhancer 
be configured to coat single microneedles, in-plane rows of 
microneedles (see, e.g., FI GS. lA-B ), and out-of-plane arrays 
ofmicroneedles (see, e.g., FIG. lC). 60 will increase the coating thickness by increasing the film 
thickness of the entrained liquid during withdrawal. How-
ever, the requirement of coating liquid surface tension being 
lower than the microneedle material can be overcome by 
In another embodiment, the physical mask may be 
designed to act as a coating liquid reservoir or reservoirs. For 
instance, the physical mask may include reservoirs, closed at 
one end, that can be filled with the coating liquid (see, e.g., 
FIG. lOB). Single microneedles or multiple microneedles of 65 
an array can be dipped into each reservoir or groove. Typi-
cally, the apertures of the mask have a closed bottom, the 
conducting the coating process at a rate faster than is needed 
to achieve thermodynamic equilibrium. For instance, by 
increasing the viscosity and withdrawing at a rapid speed, the 
microneedle will entrain a significant volume of the liquid on 
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the surface. If the solvent then evaporates before the liquid 
film can contract to form an island in the middle of the 
microneedle surface, the solid coating will become uniformly 
deposited onto the microneedles. Another way to overcome 
the surface tension barrier to obtain uniform coatings is to use 
18 
ylene terephthalate (PET) carrier tape first perforated with 
holes corresponding to the microneedles can be attached by 
slipping it over the microneedles using an aligmnent device. 
See FIG. 9. 
a non-aqueous solvent that has lower surface tension, possi-
bly lower than the microneedle material. Similarly, while 
coating only the pockets, advantage can be made of the 
kinetic effect by utilizing a high surface energy liquid/solu-
tion that will not wet the microneedle surface but will fill the 10 
The present coating methods and apparatus can be readily 
adapted for commercial production. For instances, automated 
systems are known, which can be used or readily adapted to 
sequentially grasp, position, dip, and release small parts, such 
as microneedles or microneedle arrays in an assembly-line 
fashion. 
pockets. Again, the speed must be sufficiently slow so that 
liquid does not entrain on the surface, but only gets into the 
pockets. 
Uses of the Microneedle Devices and Patches 
The microneedle devices described herein may be used to 
One factor for liquid 'pocket' coatings is that the all of the 
liquid formulation must have sufficient viscosity and low 15 
vapor pressure so that it can remain in the pockets for a 
sufficient duration to permit packaging and storage (e.g., 
under inert atmosphere and overpressure conditions) to sub-
stantially prevent vaporization. In another embodiment, the 
liquid coating may contain dissolved solids, which again 20 
must be sufficient to form a continuous film once the volatile 
deliver substances into and through the various biological 
tissues. In a preferred application, the microneedle devices 
are used to deliver a drug, particularly a therapeutic, prophy-
lactic, or diagnostic agent into the skin, sclera, or other bio-
logical tissue of a patient. As used herein, the term "patient" 
refers to a human, animal, or other living organism in need of 
therapeutic, diagnostic, or prophylactic intervention. In one 
embodiment, the drug formulation is one which undergoes a 
phase change upon administration. For instance, a solid drug 
solvent has evaporated. 
Microneedle Array Patches 
The microneedle device may be in the form of a patch for 
application to the skin of a patient. The patch may include 
one, or more preferably an array of tens or hundreds of 
microneedles (e.g., between 50 and 500) and an adhesive 
component to secure the patch to the skin. The patches may be 
fabricated using either multiple linear rows of in-plane 
microneedles, individual arrays of out-of-plane micron-
eedles, or combinations thereof. 
The adhesive component may be in the form of a flexible or 
rigid substrate which includes a pressure sensitive adhesive as 
known in the art. 
In one embodiment, the microneedles and adhesive com-
ponent are configured such that the microneedles extend 
through apertures in the adhesive layer. Individual micron-
eedles or subgroups of microneedles (e.g., rows) can extend 
through a single aperture. By having the adhesive surface 
adjacent the microneedles, the adhesive is able to better hold 
the microneedles down and to compensate for the recoiling-
tendency of skin and/or a rigid substrate for out-of-plane 
microneedles. 
In one embodiment, in-plane microneedles are fabricated 
with a uniform adhesive layer in between the microneedles. 
For example, rows ofmicroneedles can be assembled into a 
patch by forming slits (equal to the length ofan in-plane row) 
formulation may be dissolved within tissue, where it then 
diffuses out for bolus or controlled release. In a preferred 
embodiment, the drug coating is highly soluble at the physi-
25 ological pH of the patient to promote rapid delivery. 
In one application, the coated microneedles are used for 
vaccination. For example, the drug can be targeted to Langer-
hans cells residing in the epidermis for a more potent immune 
response. Advantageously, the solid phase of the antigen in 
30 the coatings may help eliminate the cold-chain (storage/trans-
portation) requirement, because the solid phase antigen may 
be more stable. 
In one embodiment, the delivery of drug particles or drug-
containing particles can be effectively delivered into a 
35 patient's skin using the present coated microneedles. Suc-
cessful delivery of microparticles or other particles (e.g., up to 
20 µmin diameter) may be enhanced by using insertion rates 
of at least 1 to 2 cm/s, by using microneedles with pockets, or 
a combination thereof. The dosage delivered may be con-
40 trolled, for example, by controlling the size of the particles, 
the number of pockets per microneedle, the total number of 
microneedles, or a combination thereof. 
The dissolution time maybe controlled from seconds to 
minutes to hours to days to weeks based on how the coating is 
45 formulated. In one example, the coating may be substantially 
insoluble and swell (e.g., hydrogels) to release the drug by 
diffusion. In another example, the coating may dissolve rap-
idly (e.g., in 10 to 20 seconds) after insertion in a patient's 
skin or sclera. 
in a material, such as polyethylene medical foam tape. Such 
cutting can be performed by any suitable technique, such as 
laser cutting. The microneedle rows can be manually inserted 50 
into each slit from the non-adhesive side of the foam tape and 
glued to the foam tape using a medical grade adhesive. The 
adhesive is then allowed to cure. Optionally, a polyethylene 
medical foam tape of sufficient thickness (e.g., 0.8 mm) can 
then be cut into a disc and affixed onto the dried glue area to 
provide a cushioned backing to facilitate pressing the patch 
during insertion. See FIG. 8. 
The amount of drug delivered within the tissue may be 
controlled, in part, by the type of microneedle used and how 
it is used. In a preferred embodiment, a coated microneedle is 
inserted into the biological tissue to allow the microneedle 
coating to dissolve and be delivered into a biological fluid. In 
55 a preferred embodiment, the microneedle is coated along a 
length equal to or less than the insertion depth so that no 
microneedle coating, and therefore no drug, is precluded 
from being delivered within the tissue. In another embodiment, a microneedle patch can be 
assembled using a complete microneedle array of out-of 
plane microneedles, a circular disc of a single-sided medical 
foam tape and a think double-sided medical tape. In the 
middle of the disc, a rectangular piece of adhesive release 
liner equal in dimensions to the periphery of the array can be 
cut out and peeled off. The stainless steel microneedle array 
can then be attached to this exposed adhesive. To provide a 
layer of pressure-sensitive adhesive on the stainless steel 
substrate of the affixed array itself, a double-sided, polyeth-
The present methods for delivering a drug to a biological 
60 tissue include the step ofinserting at least one coated micron-
eedle into the biological tissue. The initial insertion depth of 
the microneedle may be between 200 µm and 5000 µm (e.g., 
more than 250 µm, 500 µm, 800 µm, or 1000 µm, and e.g., less 
than 4000 µm, 3000 µm, 2500 µm, 2000 µm, 1800 µm, or 1500 
65 µm). In one embodiment, the insertion depth is between 200 
and 1500 µm. As used herein, the terms "insertion depth" and 
the process of "inserting" the microneedle into biological 
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tissue refer to the movement of the microneedle into the 
surface of the skin, and this depth includes both the distance 
the tissue is deformed (by the microneedle) and the distance 
the tissue is penetrated by the microneedle. The term "pen-
etration depth" refers to the non-deformative incursion of the 
microneedle into the tissue. In other words, insertion depth 
equals penetration distance plus deformation distance under 
the tip of the microneedle. 
There are various methods to control the insertion depth. In 
one embodiment, the microneedles are designed to have a 
length equal to the desired penetration depth. In another 
embodiment, the microneedles are designed to have a length 
longer than the desired penetration depth, but the micron-
eedles are only inserted part way into the tissue. Partial inser-
tion may be controlled by the mechanical properties of the 
tissue, which bends and dimples during the microneedle 
insertion process. In this way, as the microneedle is inserted 
into the tissue, its movement partially bends the tissue and 
partially penetrates into the tissue. By controlling the degree 
20 
ity associated with it. In an application for sensing based on 
binding to a substrate or reaction mediated by an enzyme, the 
substrate or enzyme can be immobilized on at least a portion 
of the surface of the microneedle. In another embodiment, a 
wave guide can be incorporated into the microneedle device 
to direct light to a specific location, or for detection, for 
example, using means such as a pH dye for color evaluation. 
Similarly, heat, electricity, light or other energy forms may be 
precisely transmitted to directly stimulate, damage, or heal a 
10 
specific tissue or for diagnostic purposes. In one example, the 
microneedle coating may release a diagnostic agent and the 
microneedle detects a reaction product following reaction of 
the diagnostic agent with an analyte in vivo. In another 
15 example, the microneedle may be dual functional, delivering 
a drug via the coating and serving as a sensor not directly 
related to the drug delivered. 
The present invention may be further understood with ref-
erence to the following non-limiting examples. 
to which the tissue bends, the depth ofmicroneedle penetra- 20 
ti on into the tissue can be controlled. In one embodiment, the 
microneedles are inserted into the tissue using a drilling or 
vibrating action. In this way, the microneedles can be inserted 
EXAMPLE 1 
Fabrication of Coated Microneedles 
to a desired depth by, for example, drilling the microneedles 
a desired number of rotations, which corresponds to a desired 25 
depth into the tissue. See, e.g., U.S. Patent Application Pub-
lication No. 20050137525 Al to Wang et al., which is incor-
porated herein by reference in its entirety. 
Metal microneedles were laser cut, electropolished, and 
then coated with various coating materials. Coated single 
microneedles and coated microneedle arrays were produced. 
Forming the Microneedle Structures 
In another embodiment, the microneedle insertion depth 
may be controlled by mechanical means. For example, the 30 
insertion of a longer microneedle may be physically limited 
Solid microneedles were cut from stainless steel sheets 
(Trinity Brand Industries, SS 304, 75 µm thick; McMaster-
Carr, Atlanta, Ga., USA) using an infrared laser (Resonetics 
Maestro, Nashua, N.H., USA), guided by CAD/CAM design, 
using techniques known in the art. Microneedles were pre-
to insert only up to a pre-specified length by encasing the 
microneedle (or microneedles or array) in a sheath with only 
part of the microneedle protruding out for tissue insertion. 
Alternatively, the microneedle or array may be secured onto a 35 
micropositioner which can control the depth of tissue inser-
tion. The depth of insertion also may be controlled by the 
geometry of the microneedle, such as a widening of the 
needle, by the speed of insertion, where more rapid insertion 
generally results in deeper insertion depth, and/ or by control- 40 
ling skin mechanics, e.g., by stretching the skin which gen-
erally facilitates deeper insertion. 
pared as single microneedles, individual rows of micron-
eedles, or as two-dimensional arrays ofmicroneedles. 
Microneedles were also made with a variety of shapes in 
increasingly complex geometries using laser etching. First, 
microneedles of different lengths and widths with a constant 
tip angle of 55° were created (FIG. 3A). Next, microneedles 
were made with small through-holes (i.e., "pockets") of dif-
ferent shapes and sizes in the shafts of the microneedles (FIG. 
The microneedles may be vibrated following insertion or 
during retraction to facilitate separation of the coating from 
the microneedle. 
In various embodiments, the methods may be adapted to 
deliver the drug formulation specifically to the epidermis, 
dermis, or subcutaneous tissue. The method may include 
essentially any means known for controlling deformation of 
the biological barrier during the microneedle insertion pro-
cess. For instance, deformation of the biological tissue may 
be intentionally reduced by performing the insertion step with 
control of microneedle velocity, microneedle vibration, 
microneedle rotation, tissue stretching, or a combination 
thereof. 
The microneedle devices also may be adapted to use the 
one or more microneedles as a sensor to detect analytes, 
electrical activity, and optical or other signals. The sensor 
may include sensors of pressure, temperature, chemicals, 
and/or electromagnetic fields (e.g., light). Biosensors can be 
located on the microneedle surface, inside a hollow or porous 
microneedle, or inside a device in communication with the 
body tissue via the microneedle (solid, hollow, or porous). 
The microneedle biosensor can be any of the four classes of 
principal transducers: potentiometric, amperometric, optical, 
and physiochemical. In one embodiment, a microneedle is 
coated with a drug formulation that has a sensing functional-
3B). Microscopic examination showed that the inside sur-
faces of these pockets were smooth and clean. Microneedles 
45 with grooved surfaces in the form of valleys and ridges were 
also made. Different patterns of valleys were successfully 
fabricated with uniform cleanliness and smoothness (FIG. 
3C). The out-of-plane microneedles were prepared by manu-
ally pushing out at a 90° angle the microneedles that had been 
50 cut into stainless steel sheets (FIG. 3D). 
Electropolishing 
Because laser-cutting stainless steel produced micron-
eedles with rough edges covered with slag deposits (FIG. 
2A), an electropolishing technique was used to remove slag 
55 from the microneedles. The microneedles were electropol-
ished in a solution containing glycerin, ortho-phosphoric acid 
(85%) and water in a ratio of 6:3: 1 by volume (Fisher Chemi-
cals, Fair Lawn, N.J., USA). A copper plate was used as the 
cathode, while the microneedles served as the anode. The 
60 anode was vibrated at a frequency of 10 Hz throughout the 
electropolishing process (current density of 1.8 mA/mm2 ) 
using a custom built vibrating device to help remove gas 
bubbles generated at the anodic surface during electropolish-
ing. The electropolishing process yielded microneedles with 
65 smooth surfaces and sharp tips (tip radius 0.5 to 1 µm) (FIG. 
2B). The electropolishing process reduced the thickness of 
the microneedles to 50 µm. 
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Microneedle Coating 
The electropolished microneedles were then coated with 
different molecules using a custom micron-scale, dip-coating 
process and specially formulated coating solutions. The 
micro-dip-coating devices and methods were used to localize 
coatings to only microneedle shafts for both single micron-
eedles (FIG. 4A) and microneedle arrays (FIG. 4B). 
22 
alignment with the dip-holes, and held in place using a mag-
net. To coat the microneedles, the microneedle-array holder 
was manually slid down the rod to dip the microneedles of the 
array into the 50 dip-holes below. 
The coating solution included 1 % (weight/volume%) car-
boxymethylcellulose sodium salt (low viscosity, USP grade, 
CarboMer, San Diego, Calif., USA), 0.5% (weight/volume 
%)) Lutrol F-68 NF (BASF, Mt. Olive, N.J., USA), and a 
model drug. The surface tension and viscosity of the coating 
Single microneedles were dip-coated by horizontally dip-
ping the microneedle into 20-30 µI of coating solution held as 
a droplet on the tip of a 200 µI large-orifice pipette tip (Cata-
logue #21-197-2A, Fisher Scientific). The large-orifice 
pipette tip was mounted horizontally in a clamp and the 
microneedle was mounted opposite to it on a manual linear 
micropositioner (A1506Kl-Sl.5 Unislide, Velmex, Bloom-
field, N.Y., USA). Immersion and withdrawal of the micron-
eedle into the liquid droplet was performed manually by 
moving the microneedle while viewing under a stereomicro-
scope (SZX12, Olympus America). 
10 solutions were modified with additives in order to deposit 
(more) uniform coatings on the microneedles. The model 
drugs tested included 0.01 % sulforhodamine (Molecular 
Probes, Eugene, Oreg.), 0.01 % calcein (Sigma, St. Louis, 
Mo., USA), 3% vitamin B (Fisher Chemicals), 1% bovine 
Linear rows of microneedles were dip coated using a cus-
tom designed coating device, which included a coating solu-
tion reservoir and a micropositioning dip coater. As illustrated 
in FIG. lA, the coating-solution reservoir of the micro-dip 
coating device consisted of two laminated parts: a 'bottom 
plate' and a 'cover plate', both of which were made of poly-
methylmethacrylate (McMaster-Carr). The two plates (bot-
tom and cover plates) were aligned and adhered to each other 
using methylene chloride solvent bonding. The bottom plate 
had a central feeding channel (1 mm deepx0.5 mm wide) 
machined into one of its faces, with a through-hole drilled 
across to the other face, which acted as the inlet port to fill the 
channel with coating solution. The cover plate had five holes 
( 400 µm diameter) drilled with the same spacing as the 
microneedles in the linear microneedle row. These "dip-
holes" acted as individual dipping reservoirs to coat each of 
the microneedles in the row. 
15 serum albumin conjugated to Texas Red (Molecular Probes), 
0.05% gWiz™ luciferase plasmid DNA (6732 base pairs, 
Aldevron, Fargo, N. Dak., USA), 2xl09 plaque forming units 
per ml of modified vaccinia virus-Ankara (Emory Univer-
sity Vaccine Center, Atlanta, Ga., USA), 10% barium sulfate 
20 (1 µm diameter particles, Fisher Chemicals), 1.2% 10-µm 
diameter latex beads (PN 6602796, Beckman Coulter, 
Miami, Fla., USA) and 8.2% 20-µm diameter latex beads (PN 
6602798, Beckman Coulter), all w/v %. DNA and virus were 
made fluorescent by incubating with YOY0-1 (Molecular 
25 Probes) at a dye:base pair/virus ratio of 1:5 for 1 hat room 
temperature in the dark. These drug materials selected for 
coating ranged in size from small molecules ( calcein-0.6 nm) 
to larger microparticles (20 µm latex beads) and included 
inorganic materials (barium sulfate), organic materials (la-
30 tex), and materials ofbiological origin (protein-bovine serum 
albumin, plasmid DNA-luciferase plasmid, and virus-modi-
fied vaccinia). All were reproducibly coated onto the micron-
eedles, with coatings uniform across the entire microneedle 
length (representative images, FIG. 5). 
35 
To enable three-dimensional alignment and dipping of 
microneedle rows into the dip-holes, three linear-microposi-
tioners were assembled on a flat acrylic plate (FIG. lB). The 
first micropositioner (x-micropositioner: A1503Kl-Sl.5 
Unislide, Velmex) was used to position the linearmicroneedle 40 
array. The other two micropositioners were assembled 
stacked on one another on the acrylic plate to create a com-
posite y-z motion micropositioner (two A1503Kl-Sl .5 Unis-
lides, Velmex) that positioned the coating solution reservoir. 
Together, the three micropositioners permitted the alignment 45 
of the linear microneedle array to the dip-holes. The x-mi-
cropositioner was used to horizontally move the micron-
eedles into and out of the dip-holes. The coating process was 
performed manually while viewing under a stereomicroscope 
(SZX12, Olympus). Control over the coating length on the 50 
microneedle shaft was exercised manually using the x-mi-
cropositioner. Tolerance for misalignment was included by 
designing the dip-hole diameter to be twice the width of the 
microneedles. Five in-plane microneedles containing five 
microneedles each were coated to predetermined lengths of 55 
30%, 50%, 75% and 100% length coverage (FIGS. 4C1 to 
4C5 ). 
Microneedle arrays were dip-coated using a method and 
dipping device similar to that used to coat linear rows of 
microneedles. The coating-solution reservoir and the micron- 60 
eedle-array holder were pre-aligned opposite to each other on 
a vertical rod. The cover plate of the coating-solution reser-
voir contained 50 dip-holes at the same spacing as the micron-
eedles in the array. The coating-solution reservoir was sta-
tionary, while the microneedle-array holder could be slid up 65 
and down the rod. Pins were provided on the microneedle-
array holder to position a microneedle array on the holder in 
EXAMPLE2 
Assembly of Coated Microneedle Patches 
Coated microneedle arrays, made as in Example 1, were 
assembled into transdermal patches containing pressure-sen-
sitive adhesive to adhere to the skin. To secure microneedles 
in the skin at all times until ready to be removed, micron-
eedles were integrated into a Band-Aid-like patch. This patch 
had pressure-sensitive adhesive on one complete side, with 
microneedles protruding therefrom. The adhesive secured the 
microneedles and compensated for the recoiling tendency of 
the skin and the rigid stainless steel substrate of out-of-plane 
microneedles. These patches were fabricated using either 
multiple linear rows of in-plane microneedles or individual 
arrays of out-of-plane microneedles. 
Microneedle Patches Using Multiple Rows of Micron-
eedles 
In-plane microneedles were fabricated with a uniform 
adhesive layer in between the microneedles. In this example, 
a set of ten rows of microneedles, containing five micron-
eedles each, was assembled into a patch of 50 microneedles. 
First, ten slits, each 75 µm wide and 7.7 mm long (i.e., equal 
to the length of an in-plane row) were laser cut into a 1.6 
mm-thick, single-sided polyethylene medical foam tape 
(TM9716, MACtac, Stow, Ohio) using a C02 laser 
(LS500XL, New Hermes, Duluth, Ga., USA). The ten 
microneedle rows were then manually inserted into each slit 
from the non-adhesive side of the foam tape and glued to the 
foam tape using a medical grade adhesive (Loctite 4541, 
Rocky Hill, Conn., USA). The adhesive was allowed to cure 
for 24 hours. A polyethylene medical foam tape (0.8 mm 
US 9,364,426 B2 
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thick; TM9942, MACtac) was then cut into a disc of 16 mm 
diameter and affixed onto the dried glue area to provide a 
cushioned backing to facilitate pressing the patch during 
insertion. 
Microneedle Patches Using Complete Microneedle Arrays 
24 
Delivery of Microparticles 
For particle delivery assessment, single microneedles 
coated with barium sulfate particles (1 µm diameter, as mea-
sured by scanning electron microscopy), or latex beads (10 or 
20 µm diameter), made as in Example 1, were inserted into 
pig cadaver skin for 1 min (n=3 microneedles for each inser-
tion). After removing the microneedles, micrographs of 
coated microneedles and histological skin sections were col-
lected. Digital X-ray imaging to detect barium sulfate was 
10 
done using a Faxitron MX20 cabinet X-ray (Faxitron X-Ray, 
Wheeling, Ill., USA). 
To assemble a microneedle patch using a complete micron-
eedle array of out-of plane microneedles, a circular disc of 20 
mm diameter was first cut from a 0.8 mm-thick, single-sided 
medical foam tape (TM9942, MACtac) using a C02 laser. In 
the middle of this disc, a rectangular piece of the adhesive 
release liner equal in dimensions to the periphery of the array 
(i.e., 12 mmx12 mm) was cut out using the C02 laser and 
peeled off. The stainless steel microneedle array was then 
attached to this exposed adhesive. To provide a layer of pres-
sure-sensitive adhesive on the stainless steel substrate of the 
affixed array itself, a double-sided, polyethylene terephtha-
late (PET) carrier tape (63.5 µm thick; T04314A, MACtac) 
was attached as follows. The PET film was first perforated 
with holes of 400 µm diameter at the same spacing as the 20 
microneedles using a C02 laser. The tape was then slipped 
over the microneedles using a custom-built alignment device 
and pressed to stick against the stainless steel substrate. 
EXAMPLE3 
In vitro Dissolution of Microneedle Coating 
At a slow speed of approximately 0.5 to 1 mm/s, barium 
sulfate particles were delivered into pig skin without wiping-
off on the surface, while latex beads 10 and 20 µmin diameter 
were wiped off on the skin surface. At a higher insertion speed 
15 of approximately 1 to 2 emfs, the momentum of the micron-
eedles was able to carry the 10 µm diameter beads coated on 
microneedles into the skin. However, the 20 µm diameter 
beads were still found as residue on the skin surface. The 20 
25 
µm diameter latex beads were delivered into the skin after 
loading them into the hollow protective cavity of the 'pock-
ets' ( 400 µm longx50 µm widex50 µm deep) and delivering at 
1 to 2 cm/s. Delivery of microparticles into the skin from 
particle-coated microneedles was achieved. 
EXAMPLE 5 
In vivo and In vitro Insertion of Microneedle Arrays 
into Human Skin 
To assess the in vitro dissolution time, single microneedles 
(n=3) coated with vitamin B, calcein, or sulforhodamine, 30 
made as in Example 1, were inserted into pig cadaver skin for 
For in vitro testing, out-of-plane microneedle arrays (n=3) 
were coated and assembled into patches as in Example 2, and 
then manually inserted into human cadaver skin for 1 min. 
After 1 min, the patch was removed and visually examined by 
brightfield microscopy to qualitatively assess the amount of 
residual coating left on the microneedles. The human cadaver 
skin was also imaged by brightfield microscopy to assess 
10 s or 20 s. Upon removal, these microneedles were imaged 
by fluorescence microscopy to detect residual coating. After 
10 s insertion, a majority of the coating was dissolved. After 
20 s insertion, the microneedle coating was completely dis- 35 
solved. A sulforhodamine-coated microneedle showed simi-
lar dissolution and release into skin. 
EXAMPLE4 
Delivery of Molecules and Particles by Coated 
Microneedles 
Delivery from Individual Microneedles In Vitro 
To further determine if the drug materials coated on the 
microneedles are actually delivered into the skin, single 
microneedles (n=3) coated with calcein or sulforhodamine, 
made as in Example 1, were inserted into pig cadaver skin for 
20 s and removed. After removing the microneedles, fluores-
cence micrographs of coated microneedles and histological 
skin sections were collected using an Olympus IX70 fluores-
cent microscope with a CCD camera (RT Slider, Diagnostic 
Instruments). Brightfield micro graphs were collected using 
release and delivery of coatings into the skin. Visual exami-
nation of the coated patch after insertion into the skin in vitro 
showed as light streaks along the length of the microneedles 
40 that approximately 10% of the coating remained on the 
microneedles. Surface examination of the treated skin 
showed an array of blue dots corresponding to microneedle 
penetration and coating deposition from the array. 
For in vivo analysis, out-of-plane arrays of non-coated 
45 microneedles, made in Example 1, were autoclaved and 
manually applied onto the forearms of human subjects (n=3) 
for 30 s. Gentian violet was then applied to the treated site for 
1 min and wiped away using isopropanol swabs. The gentian 
violet selectively stained the sites of skin perforation, which 
50 identified the sites of microneedle insertion. Dot arrays cor-
responding to array of microneedle penetrations were 
observed on the forearms. The subjects (n=3) did not report 
any discomfort upon insertion of the arrays. 
One may reasonably infer from the results that arrays of 
55 microneedles can be coated with a solid drug formulation and 
integrated into a patch, which subsequently may be applied to 
human skin for delivery of drug into the skin without patient 
discomfort. 
an Olympus SZX12 stereomicroscope with a CCD camera 
(Leica DC 300, Leica Microsystems, Bannockburn, Ill., 
USA). Histological examination of pig cadaver skin was con-
ducted on frozen sections. Pig cadaver skin was pierced with 
microneedles for 20 s, frozen in OCT compound (Tissue-Tek, 
4583, Sakura Finetek, Torrance, Calif., USA), and cut into 10 
µm-thick sections using a cryostat (Cryo-Star HM 560MV, 60 
Microm, Waldorf, Germany). 
EXAMPLE 6 
No residue was observed on the skin after insertion, and 
examination of histology sections of the pig skin revealed 
distribution of calcein along the periphery of the insertion 
point. Similar results were also observed for sulforhodamine, 65 
suggesting that the results are generally applicable to differ-
ent molecules. 
Fabrication ofMicroneedles with Various Coating 
Compositions 
Stainless steel single microneedles, in-plane microneedle 
rows, or out-of-plane microneedle arrays were fabricated as 
described in Example 1. Various microneedle geometries 
US 9,364,426 B2 
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were drafted in AutoCAD software (Autodesk, Cupertino, 
Calif., USA) and then cut into microneedles: single micron-
eedles without pockets, single microneedles with three circu-
lar pockets each 90 µm in diameter, or single microneedles 
with a single rectangular pocket 400 µm longx50 µm wide; 
in-plane microneedle rows containing five microneedle 
shafts; or out-of-plane microneedle arrays with fifty micron-
eedles. All needles were 730 µmin length and 180 µmin 
width. In-plane microneedle rows were fabricated, each with 
five rectangular (400 µm longx50 µm wide) pockets in the 10 
microneedle shafts. 
Microneedle Coating 
26 
coating with only Tween 20 (a polyoxyethylene sorbitan 
monolaurate) solution containing sulforhodamine resulted in 
a very thin layer on the microneedle surface (FIG. 6D), while 
coating with only sucrose produced a coating which was more 
centralized on the microneedle shaft (FIG. 6E). The contrac-
tion of coating upon drying towards the center of the micron-
eedle was more prominent in the case of sucrose as compared 
to carboxymethyl cellulose. Therefore, the presence of a sur-
factant was found to help spread the coating evenly across the 
microneedle surface, while the viscosity enhancer provided a 
thicker film of coating. 
Drug-excipient interaction can lead to drug aggregation or 
decreased solubility. Scratching of Tween 20/sucrose based 
coatings on stainless steel microneedles with a hypodermic 
Using the custom designed dip-coating devices as in 
Example 1, the microneedles described in the preceding para-
graph were uniformly coated, with spatial control over the 
length being coated. Single dips were made unless otherwise 
specified. The coated microneedles were allowed to air-dry at 
least 24 h before use. 
The following aqueous formulations (weight/volume % 
unless specified otherwise) were prepared and used to coat 
the microneedles: 
15 needle revealed a waxy characteristic which was not observed 
for Lutrol F-68/carboxymethylcellulose based coatings, 
apparently because Lutrol F-68 is a solid at room temperature 
while Tween 20 is a liquid. Therefore, the present formula-
tions were based on Lutrol F-68 as the surfactant, and differ-
20 ent viscosity enhancers were tested. Thick uniform coatings 
were formed using hyaluronic acid (Formulation A4), xan-
Formulation Al 0.1 % sulforhodamine 
Formulation A2 1 % carboxymethylcellulose sodium salt (CMC, low viscosity, USP grade, 
CarboMer, San Diego, CA, USA), 0.5% Lutrol F-68 NF (BASF, Mt. Olive, NJ, 
USA), 0.1 % sulforhodamine (Molecular Probes, Eugene, OR, USA) 
FormulationA3 52% (wt/wt%) sucrose, 0.2%(wt/wt %) Tween 20, 0.1 % sulforhodamine 
Formulation A4 0.1 % sulforhodamine, 0.5% Lutrol F-68 NF, 0.5% hyaluronic acid 
Formulation AS 0.1 % sulforhodamine, 0.5% Lutrol F-68 NF, 0.5% xanthan gum 
Formulation A6 0.1 % sulforhodamine, 0.5% Lutrol F-68 NF, 1 % sodium alginate 
FormulationA7 0.1% sulforhodamine, 0.5% Lutrol F-68 NF, 5% polyvinylpyrrolidone 
FormulationA8 0.1% sulforhodamine, 0.5% Lutrol F-68 NF, 52% (wt/wt%) sucrose 
FormulationA9 25% sucrose, 0.1 % sulforhodarnine 
FormulationAlO 80% (vol/vol%) glycerol, 20% (vol/vol%) of0.1 % sulforhodamine 
Formulation All 1% carboxymethylcellulose sodium salt, 0.5%, Lutrol F-68 NF, 0.2%, sodium 
fluoresce in 
FormulationA12 80% (vol/vol%) glycerol, 20% (vol/vol%) green food dye 
FormulationA13 80% (vol/vol%) glycerol, 20% (vol/vol%) amber food dye 
FormulationA14 80% (vol/vol%) glycerol, 20% (vol/vol%) red food dye 
In addition, the following organic solvent formulations 
(weight/volume% unless specified otherwise) were prepared 
and used to coat the microneedles: 
40 
than gum (Formulation AS), sodium alginate (Formulation 
A6), polyvinylpyrollidone (Formulation A7) and sucrose 
(FormulationA8) as the viscosity enhancers. From this infor-
mation, one may envision that concentrations of these or other 
viscosity enhancers or combinations thereof may be tailored 
Formulation 01 5% poly(lactic-co-glycolic acid) (PLGA) in acetonitrile 
Formulation 02 5% polyvinylpyrrolidone, 0.1 % curcumin in ethanol 
Formulation 03 5% PLGA, 0.03% sulforhodamine in acetonitrile 
45 using routine experimentation to produce coating solution 
characteristics specific for a wide variety different drug mol-
ecules. 
Effect ofViscosity and Surface Tension 
To identify the effect of surface tension and viscosity on 
50 
coating uniformity, two surfactant and viscosity enhancer 
systems were used to coat single microneedles (n=3) indi-
vidually and then both combined using sulforhodamine as the 
model drug to help visualize the coatings. Dipped micron-
eedles were air-dried for 24 hours and examined under Olym- 55 
pus IX70 fluorescent microscope with a CCD camera (RT 
Slider, Diagnostic Instruments, Sterling Heights, Mich., 
USA) to assess coating uniformity. 
Attempts to coat with sulforhodamine in water (Formula-
tion Al) did not produce a coating. Using sodium salt of 60 
carboxymethylcellulose or Lutrol F-68 NF, the coatings were 
found to be very thin (FIG. 6A) or localize away from the 
microneedle periphery towards the center (FIG. 6B), respec-
tively. However, the combination (FormulationA2) produced 
good thick uniform coatings (FIG. 6C). A similar trend was 65 
observed for Formulation A3, as a thick uniform coating 
across the entire needle surface (FIG. 6F) was formed. A 
EXAMPLE 7 
Surface Modification ofMicroneedles by Precoating 
In an effort to enhance the application of an aqueous coat-
ing solution to microneedles in a coating process without the 
use of a surfactant in the coating solution, the surface prop-
erties of the stainless steel microneedles produced in 
Example 6 were modified by (pre )coating the microneedles 
with a thin silicon dioxide layer (0.1 µm), in order to render 
the microneedle surface more hydrophilic. Silicon dioxide 
was deposited using a conventional vapor deposition method. 
Then, the microneedles were coated with an aqueous sulfor-
hodamine solution. This resulted in a uniform but thin coating 
(less than 1 to 2 µm). 
In another test, the stainless steel microneedles were (pre) 
coated with PLGA by dipping the microneedles in Formula-
tion 01, in order to make the microneedles hydrophobic. 
After drying, these surface modified microneedles were 
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dipped into Formulation Al, dried, and examined under a 
fluorescent microscope to check for coating uniformity. 
Unexpectedly, this surface modification also resulted in a 
uniform coating using just water and sulforhodamine solu-
tion. The coating was relatively thin (less than 1 to 2 µm), 
presumably because the coating solution did not include a 
viscosity enhancer, which it is would have yielded a thicker 
film and coating. 
28 
EXAMPLE 10 
Coating Microneedles Having Pockets 
These results indicate that, for coating processes, the 
dynamic contact angle is more important than the static equi-
librium contact angle. That is, during withdrawal of the 
microneedle from the coating solution, a liquid film becomes 
entrained on the PLGA surface. As the entrainment volume is 
small, the aqueous solvent rapidly evaporates to yield the 
solid coating. Surface modification of microneedles is a use-
ful tool for controlling coating uniformity, and may be par-
ticularly well suited for sensitive protein solutions, given that 
protein solutions are often inherently viscous and will itself 
provide the necessary viscosity enhancement for thicker coat-
ings. 
Single microneedles having rectangular pockets ( 400 µm 
long and 50 µm wide) made as described in Example 6 were 
dipped into FormulationA2, FormulationA9, or Formulation 
AlO. The process for coating the microneedles with Formu-
lation A2 consisted of six dips with a temporal space of 6 s 
10 between dips. Coated microneedles were examined under a 
fluorescent microscope after drying for 24 hours. 
With Formulation A2, both the pockets and the solid sur-
face of microneedles were coated. However, with Formula-
15 tion A9, which omits the surfactant from and increases the 
solids content in the coating solution, only the pockets of the 
microneedle were coated. Similarly, dipping microneedles in 
the viscous glycerol solution (FormulationAl 0) helped to fill 
the pockets without coating the microneedle surfaces. The 
20 liquid in the pockets completely evaporated in approximately 
24 hours at ambient conditions. 
EXAMPLES 
In a similar process, microneedles were coated with pro-
pylene glycol, producing microneedles having liquid-filled 
pockets. These liquid pockets could be made more stable by 
Release of Hydrophobic Coating Materials from 
Microneedles 
Single microneedles were coated with Formulation 02, as 
25 storing under pressure in a nitrogen atmosphere. In one appli-
cation of liquid-filled pocket microneedles, the liquid based 
drug formulations could deliver hydrophobic drugs from an 
organic solvent, such as polypropylene glycol. 
in Example 6, and examined under a fluorescent microscope 30 
for coating uniformity. A uniform coating of the microneedle 
surfaces resulted. The microneedles dipped in Formulation 
02 were immersed in deionized (DI) water for 15 s and 
checked for loss of coating from the microneedle surface by 
visualization under the fluorescent microscope. After the 35 
water dipping, the coating was completely removed from the 
microneedles. Even though curcumin has negligible solubil-
ity in water, dissolution of the polyvinylpyrrolidone (the 
matrix of the solid coating) resulted in the microneedle coat-
ing coming off of the microneedle surface. PLGA coating 40 (Formulation 03) also resulted in a uniform coating. 
EXAMPLE9 
EXAMPLE 11 
Composite Coatings on Microneedles 
Single microneedles with or without pockets were dipped 
in different formulations, as described in Example 6, in 
sequences to produce coatings of multiple molecules to gen-
erate different drug release profiles. Four different composite 
coating schemes were evaluated: 
(1) pocketed microneedles with three circular pockets (90 
µm diameter each) dipped into Formulation Al2, DI water, 
Formulation A13, DI water, and Formulation Al4 in that 
sequence. At each DI water step in Step (1 ), the portion of the 
microneedle dipped was decreased by one pocket to retain the 
Coating Microneedles Using Molten Materials 
Pocketed and unpocketed microneedles, made in Example 
45 formulation in it from the previous dip, while cleaning the 
water-dipped pockets. This procedure allowed sequential fill-
ing of each pocket with a different formulation. Between each 
dip and after completion of composite coatings, microneedles 
6, were dip coated into molten lidocaine and polyethylene 
glycol (PEG). Single microneedles with or without rectangu- 50 
lar pockets ( 400 µm longx50 µm wide) were dipped in liquid 
molten solutions, which did not contain any solvent or addi-
tives, of lidocaine at 100° C. or PEG (MW 1500) at 55° C. 
each containing less than 0.01 % sulforhodamine (added 
solely to help in coating visualization), cooled and air dried 55 
for 24 h, and examined under a fluorescent microscope for 
coating uniformity. The lidocaine molten solution was rela-
tively viscous, and the resulting coatings covered the entire 
surface in both unpocketed and pocketed microneedles. PEG, 
however, produced coating only in the microneedle pocket. 60 
This phenomenon occurred because molten PEG has high 
surface tension. Using the molten liquid approach, micron-
eedles can be coated with a variety of drugs in their pure state 
(e.g., lidocaine) or with drug-containing matrix materials 
without solvent by using a molten liquid as a dissolution 65 
medium for a solid drug (e.g., dexamathasone drug dissolved 
in molten PEG). 
were allowed to dry and imaged under a fluorescent micro-
scope; 
(2) unpocketed microneedles dipped six times into Formu-
lation 03 and then dipped six times into Formulation All, 
which was intended to produce a device that can provide a 
release profile of a burst release followed by slow release; 
(3) unpocketed microneedles dipped into FormulationA2, 
Formulation 01, and FormulationAl l in that sequence; and 
( 4) microneedles with a rectangular pocket ( 400 µmx50 
µm) dipped into Formulation A9, Formulation 01, and For-
mulation All in sequence. 
After fabrication of the composite coated microneedles 
was completed, the microneedles were dipped into DI water 
for 1 min to assess dissolution/drug release. The dipping 
process caused the water-soluble layers to dissolve, leaving 
the PLGA layers intact on the microneedles. These composite 
coatings can therefore be tailored to meet drug delivery 
requirements either for bolus delivery or controlled delivery 
of single or multiple drugs. 
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EXAMPLE 12 
Mass of Coating on Microneedles 
To identify parameters important to controlling the total 
mass of coating (in order to control dosage), four coating 
parameters were varied in preparing coating microneedles, 
which were made as in Example 6. The parameters were (a) 
concentration of drug in the coating solution, (b) number of 
dips during coating, ( c) number of microneedles in the array, 10 
and ( d) pocketed or unpocketed microneedles for drug coated 
onto microneedles, with vitamin B as the model drug. 
In-plane rows of microneedles were dipped into a solution 
containing 1 % sodium salt of carboxymethyl cellulose, 0.5% 
Lutrol F-68 NF, and different concentrations of vitamin B. 15 
For parameter (a), vitamin B was used at 0.01 %, 0.1%, 1 %, 
2%, 3%, and 4% concentrations (n=5 rows for each concen-
tration) with 6 dips at 8 s interval. For parameter (b ), a 3% 
vitamin B concentration was used with 1, 3, 6, 12, or 24 dips 
at 8 s intervals (n=5 rows for each dip number). For parameter 20 
( c ), a 3% vitamin B concentration was used with out-of-plane 
arrays having 5 or 50 needles (n=3 arrays for each row num-
ber). For parameter ( d), in-plane rows each with five micron-
eedles having a rectangular pocket (400 µmx50 µm) were 
dipped into a formulation containing 1%or3% vitamin Band 25 
25% sucrose. All coated microneedles were allowed to dry for 
at least 24 hr and imaged using brightfield microscopy. 
The mass of vitamin B in the coatings was then determined 
by dissolving the vitamin B containing coatings off of the 
microneedles and then measuring vitamin B concentration 30 
using fluorescence spectroscopy. The mass of vitamin B in the 
coatings was then calculated from the knowledge of the vol-
ume of DI water used to dissolve the coatings. 
An increase in the concentration of vitamin Bin the coating 
solution and in the number of coating dips was found to 35 
increase the mass of vitamin B coated onto microneedles and 
the thickness of coating, as illustrated in FIGS. 7A and 7B, 
respectively, with image insets showing thickness. At the 
maximum concentration of vitamin Bused (i.e., 4%) with six 
dips, 2.6 µg of vitamin B was coated per microneedle. At the 40 
maximum number of dips used (i.e., 24) using a 3% solution 
concentration, the mass was 6.4 µg vitamin B per micron-
eedle. Changing the number of microneedles from five to fifty 
increased the mass on the array proportionately, which sug-
gests a consistent and uniform coating across the needles of 45 
the array. The use of pockets alone for microneedle coatings, 
led to vitamin B loading of0.066 µg per microneedle. 
30 
responding to the penetration of the coated microneedles. The 
punctured spots are surrounded by a bright region around 
their periphery which indicates that the sulforhodamine was 
released from the solid coating or liquid in the pockets. 
EXAMPLE 14 
In vivo Insertion of Microneedle Arrays into Human 
Skin 
Arrays of non-coated, out-of-plane microneedles were 
assembled into adhesive patches as described in Example 2, 
sterilized using ethylene oxide, and manually applied onto the 
forearms of human subjects (n=3). After removing the adhe-
sive patch, Gentian violet was applied on the treated site for 1 
min. and wiped away using isopropanol swabs. Gentian violet 
selectively stained the sites of skin perforation. Brightfield 
imaging of the skin surface after staining showed dark dots 
which correspond to insertion points of individual micron-
eedles of the fifty needle array. The results of this example and 
the preceding one suggest that coated microneedle arrays will 
penetrate human skin and deliver their payload coatings. 
Publications cited herein and the materials for which they 
are cited are specifically incorporated by reference. Modifi-
cations and variations of the methods and devices described 
herein will be obvious to those skilled in the art from the 
foregoing detailed description. Such modifications and varia-
tions are intended to come within the scope of the appended 
claims. 
We claim: 
1. A method for coating at least one microneedle compris-
ing: 
providing a coating liquid disposed in one or more reser-
voirs, the coating liquid comprising at least one drug; 
providing a physical mask having one or more apertures 
extending therethrough, each aperture having cross-sec-
tion dimensions larger than the at least one microneedle 
to be coated; 
aligning the at least one microneedle with at least one of the 
one or more apertures; 
inserting the at least one microneedle through the aligned 
aperture and into the coating liquid, thereby coating at 
least a portion of the microneedle; and 
removing the coated microneedle from the coating liquid 
and from the aperture. 
2. The method of claim 1, wherein the physical mask 
comprises a plurality of holes or slits which closely circum-
scribe each microneedle or a single row of microneedles. Using either a single parameter or their combination, a 
pre-determined mass of vitamin B can be coated on the 
microneedles. 
3. The method of claim 2, wherein the physical mask is in 
50 the form of a rigid plate secured to the reservoir. 
EXAMPLE 13 
4. The method of claim 1, wherein the one or more reser-
voirs are defined in a secondary structure. 
In Vitro Delivery of Coating Materials from 
Microneedles into Pig Skin 
5. The method of claim 1, wherein the step of inserting the 
microneedle through the aligned aperture is done before mov-
55 ing both the physical mask and the microneedle in a manner 
to cause the microneedle to be dipped into the coating liquid. 
6. The method of claim 1, further comprising inserting the 
at least one microneedle into the same or a different coating 
liquid and then removing the microneedle from said same or 
60 different coating liquid. 
Single non-pocketed microneedles (n=3) coated with For-
mulation A2, and single pocketed (rectangular pocket---400 
µmx50 µm) microneedles (n=3) coated with Formulation 
Al 0, as described in Example 6, were inserted into pig 
cadaver skin for 20 s and removed. After removing the 
microneedles, the skin surface was examined for coating 
residue using brightfield microscopy. In addition, the pig skin 
was examinedhistologically to assess the extent of delivery of 
microneedle coatings into the skin. Histological sections of 65 
pig skin after insertion ofmicroneedles coated with Formu-
lation A2 or Formulation Al 0 contain a tear in the skin cor-
7. The method of any claim 1, wherein the at least one 
microneedle comprises one or more pockets therein. 
8. The method of claim 7, wherein the process coats sub-
stantially only the one or more pockets. 
9. The method of claim 1, wherein the coating liquid in the 
reservoir is agitated or flowed to maintain composition uni-
formity. 
US 9,364,426 B2 
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10. The method of claim 1, wherein the surface energy of 
the coating liquid is less than the surface energy of the at least 
one microneedle. 
11. The method of claim 1, wherein the coating liquid 
further comprises a viscosity enhancer. 
12. The method of claim 11, wherein the coating liquid 
further comprises a surfactant. 
13. The method of claim 1, wherein the coating liquid is 
heterogeneous. 
14. The method of claim 1, wherein the at least one micron-
eedle is formed of stainless steel, titanium, or another metal. 
15. The method of claim 1, wherein the at least one micron-
eedle is formed of a biodegradable polymer. 
10 
16. The method of claim 1, wherein the at least one micron- 15 
eedle comprises two or more microneedles. 
17. The method of claim 1, wherein the drug comprises a 
therapeutic or prophylactic agent. 
32 
18. The method of claim 1, further comprising solidifying 
the liquid coating remaining on the microneedle after remov-
ing the coated microneedle from the coating liquid and from 
the aperture. 
19. The method of claim 18, wherein the at least one 
microneedle comprises an array of 2 to 1000 microneedles 
having beveled or tapered tips. 
20. The method of claim 19, wherein the microneedles 
comprising a biodegradable polymer. 
21. The method of claim 19, wherein the coating liquid 
comprises a sugar. 
22. The method of claim 19, wherein the drug comprises a 
vaccme. 
23. The method of claim 19, wherein the coating liquid 
comprises a sugar and the drug comprises a vaccine. 
24. The method of claim 19, wherein the solidified coating 
is adapted to come off the microneedle following insertion 
into a biological tissue. 
* * * * * 
